HYPNOMIDATE

This brand name is authorized in Austria, Brazil, Croatia, Estonia, France, Malta, Netherlands, Poland, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug HYPNOMIDATE contains one active pharmaceutical ingredient (API):

1	Etomidate UNII Z22628B598 - ETOMIDATE
	Etomidate is an imidazole derivative with short-acting sedative, hypnotic, and general anesthetic properties. Etomidate appears to have gamma-aminobutyric acid (GABA) like effects, mediated through GABA-A receptor. The action enhances the inhibitory effect of GABA on the central nervous system by causing chloride channel opening events which leads to membrane hyperpolarization.
	Read more about Etomidate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HYPNOMIDATE Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01AX07	Etomidate	N Nervous system → N01 Anesthetics → N01A Anesthetics, general → N01AX Other general anesthetics
Discover more medicines within N01AX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501321050030117
EE	Ravimiamet	1851601
ES	Centro de información online de medicamentos de la AEMPS	57562
FR	Base de données publique des médicaments	63444171
GB	Medicines & Healthcare Products Regulatory Agency	76235
HR	Agencija za lijekove i medicinske proizvode	HR-H-990410340
MT	Medicines Authority	AA565/33502, AA565/33504, AA729/28401
NL	Z-Index G-Standaard, PRK	3492
PL	Rejestru Produktów Leczniczych	100030133, 100341420, 100347887, 100412260, 100439023, 100457341, 100458441
TN	Direction de la Pharmacie et du Médicament	23693011H
ZA	Health Products Regulatory Authority	M/2.2/183